BD maintains recent strong momentum in second quarter of 2014

BD has announced its financial results for the second quarter of 2014, during which it experienced year-on-year growth of 3.6 percent.

During the three months ending on March 31st 2014, the firm generated revenues of $2.07 billion (1.23 billion pounds), a strong performance that was driven by its medical segment and the continued improvement in its biosciences division.

Its performance outside the US demonstrated a more robust growth rate than its American division, while its six-month performance was also shown to be encouraging, with diluted earnings per share from continuing operations rising 2.9 percent to $2.82.

BD has reaffirmed its previously communicated currency-neutral revenue guidance range of 4.5 to 5.0 percent, based on the strength of these results.

Vincent Forlenza, chairman, chief executive officer and president of BD, said: "This consistent performance demonstrates the breadth of the growth drivers across our businesses and regions, and highlights the diversity of our portfolio."

This comes after the firm reported better-than-expected results for the first quarter of 2014, leading it to increase its targets for the full year.